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ABSTRACT 
 
This study was aimed to investigate the in-vitro deposition, the market status and the customer’s perception of 
different pressurized metered dose inhaler (pMDI) preparations, available in Bangladesh. In order to test the 
efficiency of pMDI, the in-vitro deposition of locally manufactured salmeterol xinafoate from two brands, 
considered as product A and product B, was carried out using a Twin-Stage-Impinger (TSI) and was correlated with 
the customer perception. The market status and customer’s perception has been studied through three different 
market surveys conducted on patients, (n=50), physicians (n=50) and pharmacy shops (n=50). In all three surveys 
the usage pattern of salbutamol has been found to be highest among various antiasthmatic drugs and has showed 
market share of 18.2 %. The manufacturer of this product occupied the highest market share compared with those of 
others. The in-vitro deposition of salmeterol xinafoate from both products revealed that the fine particle fractions 
(FPF, the amount of deposited salmeterol xinafoate in the lower airway of lung) of these products were within 32-
44% and deposition was observed to be higher for product A compared to product B. Both the market status and 
efficiency testing results indicated that product A showed superior performance and more efficacy compared to the 
product B.  
 
Key words: Asthma, Pressurised Metered Dose Inhaler, Fine Particle Fraction, In-vitro, Salmeterol Xinafoate and 
Salbutamol Sulphate. 
 
INTRODUCTION 
 
Asthma is a chronic inflammatory disorder of lung 
characterized by hyperactive airways, leading to 
reversible bronchoconstriction (Ramzi et al., 2002). 
An obstructive condition of respiratory tract in which 
widespread narrowing of the bronchial airways 
occurred due to asthma (Walter and Israel, 1996). 
Dust, certain food, medicines, mites, mold spores and 
pollen are considered to be the main causes of 
asthma, which attack all age groups. It is a disease 
characterised by recurrent attacks of breathlessness 
and wheezing. Asthma is a chronic health hazard in 
Bangladesh where the prevalence of asthma is quite 
high and a recent study reports showed that about 7 
million people (5.2% of total population) are 
suffering from mild to moderate asthma while the 
fundamental cause of the asthma is still unknown. 
Almost four million children or 7.4 per cent of the 
child population of the country suffer from asthma 
and majority of such patients has mild asthma 
(Hassan et al., 2002). 
 
Various types of medications in various dosage forms 
including solid tablet, liquid for oral delivery and 
inhalers for direct delivery of drugs through the 
respiratory airways, are used to manage mild to 
moderate bronchoconstriction. Of the inhalers, i.e. 
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pressurized metered dose inhalers (pMDI) and dry 
powder inhalers (DPI), pMDI are frequently used in 
Bangladesh. The drug formulation in pMDI is usually 
a suspension or solution of drug in a liquefied 
propellant.  Although pMDI are widely used in 
respiratory drug delivery, some problems have been 
associated with these devices, including the need for 
coordination of inspiratory inhalation with valve 
actuation and the use of a propellant which has 
possible adverse effects on the stratospheric ozone 
layer. Presently, there are some pMDI products 
approved by regulatory agencies with non-CFC 
propellants, i.e. hydrofluoroalkanes (HFA). However, 
the compatibility of the valves and container walls of 
some devices with HFA is also known to be 
problematic (Crowder et al., 2001). In addition, the 
drug deposition from these inhalers is not more than 
20-30% (Steckel and Mueller, 1997). Dry powder 
inhaler (DPI) contains the drug in a powder 
formulation. Powder de-agglomeration and 
aerosolization from these formulations are achieved 
by the patient’s inspiratory airflow. This airflow 
needs to be sufficient to create an aerosol containing 
respirable particles, i.e. <5 m for lung deposition 
(Hersey, 1975). Advantages of DPI over other inhaler 
systems are the independence of breathing co-
ordination with dose actuation, the absence of 
propellants, low innate initial velocity of particles 
(reducing inertial impaction at the back of the throat) 
and the solid state drug stability. However, here in 
this paper only the pMDIs has been studied, because 
no preparation of DPI are manufactured locally at the 
time of the study. 
 
For proper management of mild to chronic asthma, 
the current available hospitals in Bangladesh have no 
such modern facilities. Although some hospitals have 
special arrangement to supply inhalers; however, this 
supply is inadequate with the increasing number of 
asthma patients. The poor patients can’t afford 
relatively expensive inhalers. The marketing 
strategies of different expensive pressurized metered 
dose inhalers may affect the consumption of these 
drugs by the patients as around 70% people, who 
suffer from asthma, are from low socio-economic 
class and can’t afford the cost effective inhalers.  
 
Therefore, the objective of this study was to 
investigate the in-vitro deposition, the market status 
and the customer’s perception of different pressurized 
metered dose inhaler (pMDI) preparations, available 
in Bangladesh. A survey was conducted to the 
patients, physicians and pharmacy shops to determine 
how antiasthmatic drugs are being used by the 
patients and the proportion of total sales of 
antiasthmatic drugs manufactured and/ or available in 
Bangladesh. In addition, the efficiency of two brands 
of Salmeterol Xinafoate and salbutamol sulphate 
pressurized metered dose inhalers, manufactured in 
Bangladesh were carried out using TSI, an instrument 
to quantify the amount of drugs deposited in the 
lower airway of lungs during respiratory delivery, to 
compare with the efficiency and marketing strategies 
of these products.  
 
MATERIALS AND METHODS 
 
A: Survey work and marketing strategies: This study 
did not conduct the survey for finding the prevalence 
of asthma disease in the surveyed area; however, the 
survey conducted to find out how the patients are 
suffering from asthma, how they are managed and 
their impact on the marketing strategies of the leading 
pharmaceuticals, who manufacture the inhalers. 
Using surveys, work primary data were collected 
from patient, doctor and pharmacy owner by 
interviewing them through a questionnaire. The 
information was collected by face to face interviews 
and discussions with each individual of patient, 
physician and chemist. Primary data were also 
collected through observation. The secondary data are 
collected through the journal, medicine report, 
articles etc. The information of inhaler profile of 
Bangladesh was collected from the secondary data. 
The sampling procedure is non-probability sampling 
because the sample size is specific number and the 
method of sampling is judgmental.  
 
Data Analysis: Collected data was organized and 
analysed by statistical methods and were interpreted 
by the relative weights and their significance. 
 
B: Drug dispersion test 
Collection of Sample: Three samples from each of 
products A and B (a preparation of Salmeterol 
Xinafoate) inhalers were collected from the retail 
pharmacy of different areas in Dhaka city 
(Bangladesh). The manufacturing date was close to 
each other to avoid difference in expiry date.  
Collected samples were covered with security seal by 
manufactures.  
 
Drug dispersion by Twin-Stage Impinger (TSI): 
The in-vitro aerosol deposition of Aerosol 
formulations has been determined using a Twin-Stage 
Impinger (TSI, Apparatus, A; British Pharmacopoea, 
2000) (Copley, UK).  
 
The actuator adapter was placed in position at the end 
of the throat so that the mouthpiece end of the 
actuator, when inserted to a depth of about 10 mm, 
lines up along the horizontal axis of the throat while 
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the open end of the actuator, which accepts the 
pressurized container, was uppermost and in the same 
vertical plane as the rest of the apparatus. 
 
A solvent of 50 % (v/v) methanol (HPLC grade) was 
used as the collection liquid with 7 and 30 ml were 
placed into stage one and stage two of the TSI 
respectively. The temperature and relative humidity 
of the surrounding environment was measured by a 
thermo-hygrometer (Shinyei TRH-CZ, Japan). A 
suitable vacuum pump (Model OD5/2, Dynavac 
Engineering, Australia) was connected to the outlet of 
the apparatus and the airflow rate was adjusted to 
60L/min at the mouthpiece (Fisher and Porter, Model 
10A3567SAX, UK).  
 
The metering valve was primed by shaking for 5 
seconds and discharged once to waste and this 
process was repeated for further four times. The 
container was again shaken for 5 seconds and 
assembled the mouthpiece end of the actuator in the 
adapter, the pump was switched on and drug was 
discharged once immediately. The assembled inhaler 
was removed from the adapter, shaken for not less 
than 5 seconds and relocated the mouthpiece end of 
the actuator for a further eight times. After 
discharging the tenth delivery, the pump was 
switched off after 5 seconds. The apparatus was then 
dismantled and the inner surface of the inlet tube to 
the lower impingement chamber and its outer surface 
that projected into the chamber (stage 2) were washed 
with 50% (v/v) methanol solution. This solution was 
combined with the collecting solvent previously kept 
in stage 2 of the apparatus. The amount of Salmeterol 
Xinafoate in this solution was determined by HPLC 
and was expressed as the fine particle fraction (FPF), 
which is defined as the amount of drug particles 
deposited in the lower stage (stage 1) of the TSI. The 
deposition of drugs from the pMDIs is very complex 
and depends upon so many factors, including 
complex physiology of respiratory tracts (Vander et 
al., 1994), co-ordination between drug actuation and 
patient’s inspiration, physicochemical properties of 
drugs and propellants, inspiratory flow rate and 
resistance of device (Hickey and Martonen, 1993; 
Martonen and Katz, 1993; Steckel and Mueller, 
1997). Therefore, it is very difficult to predict the 
amount of drugs to the lower airway of lungs from 
the inhalers. 
 
HPLC analysis of Salmeterol Xinafoate: Salmeterol 
Xinafoate was analyzed by High Performance Liquid 
Chromatography (HPLC) using a C18 column 
(μBondapak™, 3.9 x 300mm, Waters) and an UV 
detector (Waters Tunable Absorbance Detector, 
USA) at a wavelength of 252 nm. A mixture of 
methanol and 0.2% (w/v) ammonium acetate solution 
(55:45, pH ~6.9) was used as a mobile phase running 
at a flow rate of 1.0 ml/minute by a HPLC pump 
(Waters 510, USA). The peak area was recorded by 
integration (Shimadzu CR6A Chromatopack, Japan). 
The retention time of Salmeterol Xinafoate was 3.89 
minutes. The calibration plot of standard Salmeterol 
Xinafoate solution was linear over the range of 0.4-10 
μg/ml with r2=1.00.  
 
Calculation: The recovered dose (RD) was defined 
as the total amount of drug collected from stage one 
(S1) and stage two (S2). The emitted dose (ED) was 
defined as the amount of drug delivered from the 
inhaler presented as the percentage of RD. The fine 
particle fraction (FPF) was defined as the amount of 
drug particles deposited in the lower stage of the TSI 
as a percentage of the ED. Both ED and FPF were 
calculated using the following equations: 
 
 
10021 x
RD
SS
ED


        (1) 
1002 x
ED
S
FPF 
        (2) 
 
RESULTS AND DISCUSSIONS  
A: Survey work 
Survey of asthma patients: The outcome of the survey 
revealed that most of the respondents (68%) have 
been suffering from asthma for more than three years; 
12% for three years, 10% for two years and 4% for 
one year (Rashid et al., 2008). With regards to the 
epidemiology of asthma in the surveyed area, the 
outcome might not represent the severity of this 
disease of the whole country because of the limited 
numbers of patients that have been surveyed within 
three regions of the greater Dhaka city; however, this 
result would help to get an idea of the severity and 
management of asthma in these areas. Dhaka is a big 
city with very dense population and with 
environmental pollution by dust, gas, and smokes 
from malfunctioning vehicles, which cause to 
increase the severity of asthma disease. That’s why 
the number of asthma patients is increasing day by 
day in the greater Dhaka city. 
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Management of Asthma 
Prescription pattern by physicians: The prescription 
pattern by the physicians revealed that the physicians 
prescribe inhalers frequently. The survey indicated 
that 38% physicians prescribed about 80% of inhaler 
in total drugs prescribed per day and around 28% 
physicians prescribed 50% inhalers of the total 
prescription per day. Surprisingly, the survey 
indicated that 8% and 4% physicians prescribed 
100% and 90% inhalers respectively, per day. This 
pattern of prescription disclosed the severity of 
asthma patients in the surveyed area. During 
prescribing, 64% of physicians considered the 
financial condition of the patients whereas 6% 
physicians did not consider the financial condition of 
consumers, and 30% physicians discarded this 
question. Most physicians preferred according to the 
rank order of the combination of salmeterol xinafoate 
(SX), salbutamol sulphate (SS), Fluticasone 
propionate, and beclomethasone dipropionate (BD) 
(Table 1). Few physicians were found to prescribe 
other drugs such as Nedocromil, Na-chromoglycate 
and Triamcinolone acetate. It is interesting to note 
that the visiting frequency of medical representatives 
to physicians did not influence the market share of 
those products.  
 
Survey showed that physicians preferred different 
manufacturers considering the efficacy, quality, 
availability, cost of products, company image and 
motivated by personal relationship with medical 
representatives of the respective manufacturers. 
Considering the previous parameters, a multinational 
company appeared to be the high ranked 
pharmaceutical company compared with those of 
local industries. The effectiveness and good quality of 
products, although not quantitative, was concluded by 
physicians according to their interpretation of the 
patient response during treatment. However, company 
image and marketing strategies of manufacturers also 
strengthen these two parameters. 
  
Table 1: Preferred drugs by Physicians. 
Generic name of different products Weighted 
score 
Market share 
(%) 
Beclomethasone diproponate 272 5.7 
Fluticasone propionate and 
Salmeterol xinafoate 
272 2.2 
Salbutamol sulphate 298 18.2 
Salmeterol xinafoate 350 6.6 
Nedocromil sodium 213 1.2 
Sodium chromoglycate 121 2.0 
Triancenolone acetonide 184 2.4 
 
 
Usage pattern of drugs by patients: To manage 
asthma, steroids, salbutamol sulphate and salmeterol 
xinafoate pressurized metered dose inhalers (pMDIs) 
were used by 63.6%, 25% and 9.1% patients, 
respectively, either prescribed by the physicians or 
recommended by other patients who are using the 
same medicine, or influenced by the pharmacy shops. 
Out of the steroid drugs, Beclomethasone diproponate 
was found to be used frequently, compared with those 
of salbutamol sulphate and salmeterol xinafoate. 
After consulting with doctors, about 50% patients 
changed their medicines due to the less efficiency of 
inhalers. Although unacceptable, study revealed that 
around 10% patients changed their inhalers by 
themselves or by consulting with their friends who 
used that medicine; however, only 2% patients 
changed due to high price of some inhalers. This 
result revealed that drugs are not sold or used 
according the recommendation of physicians. It is 
amazing to note that about 46% of the patients 
motivated other patients to take specific brands of the 
inhaler without consulting with doctors. For example, 
around 22% of patients suggested taking salbutamol 
sulphate, whereas 12% recommended salmeterol 
xinafoate. It was unclear how one patient motivated 
other patients to buy specific brand, however, it could 
be due to better relief of asthma experienced by the 
motivator. 
 
Although inhalers are being prescribed by doctors 
either specialist or GP, uses of higher percentage of 
steroids inhaler could be a long term problem where a 
significant number of patients have a greater tendency 
to change their medication without consulting with 
their doctors. It indicated that the patients did not 
follow the physicians or mislead by pharmacy shops. 
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In this case, patients need to be familiar with the 
proper instruction to use medicaments through 
inhalers and the doctors need to inform all possible 
health hazards to the patients.  
 
The consumers were found to be aware of the quality 
of drugs before buying. The preference of buying 
medicines indicated a rank decrease in the quality, 
effectiveness, and company image (Figure 1). 
According to the effectiveness, the most preferred 
drug was Beclomethasone dipropionate compared 
with those of salbutamol sulphate and salmeterol 
xinafoate. Of the manufacturers, according to the 
patients view, a multinational industry was found to 
be the highest quality manufacturer of pMDIs and 
occupied the highest percentage of usage. A leading 
local manufacturer was ranked in the second position, 
however very close to that multinational company.
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Figure 1. Preferred parameters regarding the brands of Inhaler. 
 
Selling pattern by the pharmacy shops: From the 
survey work, about 76% (38 of 50) respondents 
revealed that they sold most of the inhaler according 
to prescription and 24% (12 of 50) did not follow the 
physician’s prescription. A major portion (74%) of 
sellers was found to influence the patients for buying 
medicines according to the prescription whereas 26% 
sellers influenced the patients to buy without 
prescription. It is surprising to note that a significant 
number of respondents (42%) said that more than 
10% of inhalers are sold as over the counter drug 
(OTC). The survey also indicated that most of the 
respondents have given priority on patient’s demand, 
effectiveness of drugs, and profit of the business 
(Table 2). Other remarkable parameters were 
prescription by physicians, product quality, 
availability of products, and good relationship with 
medical representatives (MR). The majority of the 
respondents (32%) commented that the inhaler price 
should be reasonable, 26% replied both quality and 
price and only 16% replied quality should be high.
  
Table 2: Preferred parameters of pMDIs. 
Rank Parameters Weighted score 
1 Patients demand 416 
2 Profit 225 
3 Physicians prescription 163 
4 Quality of products 159 
5 Availability of products 67 
6 Relationship with MR 32 
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Market share of different products: The market 
share of different pMDIs manufactured by different 
pharmaceutical companies was summarized in table 
1. Salbutamol sulphate captured the highest market 
share (18.2%) of the total inhalers and the next 
products were salmeterol xinafoate and steroids 
containing preparations. With regards to the market 
share of the four pharmaceutical companies who 
manufacture metered dose inhalers in Bangladesh, the 
multinational company captured the highest market 
share (48.7%, the raw data not shown in this article) 
and the second highest position occupied by a leading 
local manufacturer (38.0%, the raw data not shown in 
this article). These findings coincided with the 
company image in the perception of physicians, 
patients and pharmacy shops, who represented the 
products of those companies in the rank order of 
quality and efficacy. As discussed earlier, the market 
share of salbutamol sulphate, salmeterol xinafoate 
and becllomethasone dipropionate were found to be 
higher than those of other products and was 
consistent with the usage pattern of these drug by the 
patients either prescribed by the physicians or not. 
For the steroid preparations, a diffused pattern of 
preference revealed that physicians mostly preferred a 
brand whereas patients preferred another brand, 
meaning that those drugs were not sold according the 
prescription. Market share of inhaler in pharmacy 
varied according to the sales position of the brand, 
image and reputation of company. In this study, the 
market share was seen according to the four major 
competitive inhaler manufacturing company. It is 
clear that there are few brands among those 
competitors that indicate the super competition to 
capture the market by advertising where the law 
enforcement in controlling the advertisement were 
insufficient resulting in increasing their brand loyalty 
with physicians, patients and pharmacy shops.  
 
Part B: In-vitro drug deposition from selected 
pMDI: The in-vitro deposition of only Salmeterol 
Xinafoate contains products A and B was carried out 
and is shown in Table 3. 
  
Table 3: Results of Salmeterol dispersion from products A and B (n= 3x2; 3 samples from each 
group and 2 replicates from each samples; standard deviations are within the brackets). 
Salmeterol Xinafoate  Samples ED FPF (%) Average FPF 
Product A 1 100 49.3 
44.2 (5.4) 2 100 44.2 
3 100 38.5 
Product B 1 100 44.3 
32.3 (10.7) 2 100 23.5 
3 100 29.1 
 
The study showed that the Salmeterol xinafoate 
dispersion (FPF) from sample 1, 2 and 3 of product A 
was 49.3, 44.2 and 38.5%, respectively. In contrarily, 
the FPF from sample 1, 2 and 3 of product B was 
44.3, 23.5 and 29.1 %, respectively. There is no 
specification in any standard official books about the 
percent deposition of drugs from the inhalers during 
respiratory delivery, except that the dose content 
uniformity should be 80-120 percent. Emitted dose 
(ED) of salmeterol xinafoate from each device was 
100%; however, in- vitro deposition i.e., FPF of 
product A (FPF 44.2 ± 5.4 %) was found significantly 
(p<0.05) larger than that of product B (FPF 32.3 ± 
10.8%).  The dose variability of product B (standard 
deviation, 10.8) was higher than that of product A 
(5.4). The reason behind this was unknown; however, 
the device resistance could be a factor in influencing 
FPF and dose variability. The first sample of product 
A produced good deposition, FPF 45-54%, 2nd 
sample, FPF 44-46%, and 3
rd
 sample FPF 36-40%. 
Similarly product B produced very good FPF for first 
sample (FPF: 37-50%), whereas for 2nd (FPF, 21-
26%) and 3rd sample FPF 28-29%, very poor 
performance (Rashid et al., 2008).These results 
indicated that batch-to-batch variation in FPF was 
significantly (p<0.05) higher for product B compared 
with product A. Dispersion from product B has been 
also found less reproducible than that of product A. 
Further investigation in terms of determining device 
resistance and its influence in controlling dose 
delivery is warranted. 
 
Combination of survey and in-vitro dispersion of 
some selected brands: The overall marketing 
strategies, physicians and patient’s feedback on the 
quality and efficacy of only two brands (product A 
and product B) were compared with the in-vitro 
respiratory delivery of drugs from these two brands 
and the results were presented in Table 4. 
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Table 4: Different quality and marketing parameters of two brands of Salmeterol 
Xinafoate.  
Selected Parameters 
Product Drug 
deposition 
Market share Used by 
patients 
Preferences Visit 
of 
MR 
Product Manufacturer Physicians Patients Chemists  
 
A (44.2%) (18.2%) (48.7%) (25.0%) High High High 
Low 
 
B (32.3%) (6.6%) (38.0%) (9.1%) Low Low Low 
High 
 
 
 
The comparison gave an insight look on different 
quality and marketing parameters of the two brands 
of Salmeterol Xinafoate manufactured in Bangladesh. 
The in vitro deposition data showed that product A 
had superiority over B. Product A has also been 
found superior while considering different marketing 
parameters of this drug as well as previously 
described market share. However, visiting of doctors 
by medical representative (MR) was higher for 
product B than that of product A. Taking into account 
the results in Table 4, it may be concluded that 
product A was found to be superior to B considering 
all parameters used in this study. This combination of 
efficacy and quality leads to get more preference by 
the physicians, chemists and patients resulted in 
increasing market share of product A. 
 
Conclusions 
The marketing status of different pMDIs and their 
manufacturers suggested that the quality and efficacy 
of drugs were given priority by physicians, patients 
and sellers. However, there was a greater tendency 
among the patients and sellers to avoid prescription 
during buying or selling those inhalers. It was also 
found that incidences of over the counter (OTC) sale 
of inhalers and motivation by patients are practiced. 
These trends should be discouraged by providing 
adequate information to patients and chemists above 
the possible hazards of pMDI on our health. The 
combination of efficacy and drug delivery i.e. drug 
deposition of the two brands would lead to get 
preference by the physicians, chemists and patients 
and thereby affect the market share. 
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